Scinai Immunotherapeutics Ltd. (SCNI) Profit Margins
Over the twelve months to 2026-06-30, Scinai Immunotherapeutics Ltd. (SCNI) had gross margin -252.3%, operating margin -564.4%, net margin -174.8%, free cash flow margin -504.6%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SCNIScinai Immunotherapeutics Ltd.Follow SCNI — free
—
Price chart with a free account
- Market cap
- 3.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- —
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Gross margin | — | -88.1% | -202.3% | -252.3% | |
| Operating margin | -37.9% | -1312.8% | -575.3% | -564.4% | |
| Net margin | -25.4% | 728.9% | -633.6% | -174.8% | |
| FCF margin | -39.1% | -964.6% | -461.9% | -504.6% |
USD millions · SEC XBRL
Scinai Immunotherapeutics Ltd. — questions
- What is Scinai Immunotherapeutics Ltd.'s gross margin?
- -252.3% over the twelve months to 2026-06-30.
- What is Scinai Immunotherapeutics Ltd.'s operating margin?
- -564.4% over the twelve months to 2026-06-30.
- What is Scinai Immunotherapeutics Ltd.'s net profit margin?
- -174.8% over the twelve months to 2026-06-30.
Every figure on this page comes from Scinai Immunotherapeutics Ltd.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.